Monitoring and Adjustment of Medication Therapy for Patients With Heart Disease
Status: | Completed |
---|---|
Conditions: | Peripheral Vascular Disease, Cardiology |
Therapuetic Areas: | Cardiology / Vascular Diseases |
Healthy: | No |
Age Range: | 60 - 90 |
Updated: | 4/2/2016 |
Start Date: | November 2010 |
End Date: | December 2012 |
Contact: | Cassandra D Benge, PharmD |
Email: | cassandra.benge2@va.gov |
Phone: | 615-873-6019 |
A Prospective Evaluation of a Medication Therapy Management Clinic Versus Usual Medical Care in Patients Post Acute Coronary Syndrome: The MUMPS Study
Existing trials for the patient with coronary heart disease evaluate the interdisciplinary
team dynamic where pharmacists (pharmacotherapists) provide therapeutic recommendations in
the inpatient environment. To our knowledge, only other trial has evaluated the addition of
a pharmacist (or nurse practitioner) in an outpatient collaborative cardiology practice and
has found no benefit. However, the investigators believe that since a cardiology based
pharmacist (pharmacotherapist) in the Veterans Health Administration has physical assessment
skills, a shorter cycle length between appointments, and the ability to provide medication
therapy management, the pharmacotherapist should be similarly successful as seen with other
pharmacist based medication therapy management practices. The investigators will assess
effectiveness by using the combined endpoint of blood pressure and lipid treatment.
Additionally the investigators will conduct three substudies to evaluate if the pharmacist
can improve all cause mortality and cardiovascular morbidity, adherence to
antihypertensives, and patient satisfaction.
team dynamic where pharmacists (pharmacotherapists) provide therapeutic recommendations in
the inpatient environment. To our knowledge, only other trial has evaluated the addition of
a pharmacist (or nurse practitioner) in an outpatient collaborative cardiology practice and
has found no benefit. However, the investigators believe that since a cardiology based
pharmacist (pharmacotherapist) in the Veterans Health Administration has physical assessment
skills, a shorter cycle length between appointments, and the ability to provide medication
therapy management, the pharmacotherapist should be similarly successful as seen with other
pharmacist based medication therapy management practices. The investigators will assess
effectiveness by using the combined endpoint of blood pressure and lipid treatment.
Additionally the investigators will conduct three substudies to evaluate if the pharmacist
can improve all cause mortality and cardiovascular morbidity, adherence to
antihypertensives, and patient satisfaction.
Existing trials for the patient with coronary heart disease evaluate the interdisciplinary
team dynamic where pharmacists (pharmacotherapists) provide therapeutic recommendations in
the inpatient environment. To our knowledge, only other trial has evaluated the addition of
a pharmacist (or nurse practitioner) in an outpatient collaborative cardiology practice and
has found no benefit. However, the investigators believe that since a cardiology based
pharmacist (pharmacotherapist) in the Veterans Health Administration has physical assessment
skills, a shorter cycle length between appointments, and the ability to provide medication
therapy management, the pharmacotherapist should be similarly successful as seen with other
pharmacist based medication therapy management practices. The investigators will assess
effectiveness by using the combined endpoint of blood pressure and lipid treatment.
Additionally the investigators will conduct three substudies to evaluate if the pharmacist
can improve all cause mortality and cardiovascular morbidity, adherence to
antihypertensives, and patient satisfaction.
This is a randomized study comparing the use of a medication therapy management clinic
improves cardiac risk factors and recurrent hospitalization in patients admitted with an
acute coronary syndrome.
100 subjects will be enrolled as a minimum. Patients will be randomized to usual care or
enrollment in the MTM clinic where they will be seen every two months for 8 months.
The primary endpoint is blood pressure and lipid changes. Secondary endpoints include
satisfaction with pharmacists, medication habit changes, recurrent events.
team dynamic where pharmacists (pharmacotherapists) provide therapeutic recommendations in
the inpatient environment. To our knowledge, only other trial has evaluated the addition of
a pharmacist (or nurse practitioner) in an outpatient collaborative cardiology practice and
has found no benefit. However, the investigators believe that since a cardiology based
pharmacist (pharmacotherapist) in the Veterans Health Administration has physical assessment
skills, a shorter cycle length between appointments, and the ability to provide medication
therapy management, the pharmacotherapist should be similarly successful as seen with other
pharmacist based medication therapy management practices. The investigators will assess
effectiveness by using the combined endpoint of blood pressure and lipid treatment.
Additionally the investigators will conduct three substudies to evaluate if the pharmacist
can improve all cause mortality and cardiovascular morbidity, adherence to
antihypertensives, and patient satisfaction.
This is a randomized study comparing the use of a medication therapy management clinic
improves cardiac risk factors and recurrent hospitalization in patients admitted with an
acute coronary syndrome.
100 subjects will be enrolled as a minimum. Patients will be randomized to usual care or
enrollment in the MTM clinic where they will be seen every two months for 8 months.
The primary endpoint is blood pressure and lipid changes. Secondary endpoints include
satisfaction with pharmacists, medication habit changes, recurrent events.
Inclusion Criteria:
All patients with a diagnosis of ACS at the VA Tennessee Valley Healthcare System who
1. are greater than or equal to 60 years of age
2. will benefit from Medication Therapy Management (MTM):
- Have a baseline LDL >79mg/dL in the first 24 hours of acute coronary syndrome
(ACS) OR if LDL not assessed in the first 24 hours of ACS, have a recent LDL
>79mg/dL (in the last 15 months) OR not have an LDL assessed prior to or during
admission.
AND
- Have outpatient blood pressures (BP) above goal on 65% or more of assessments
within the last 15 months or a SBP >140mmHg or DBP>90mmHg or both on the last
outpatient BP assessment.
3. are enrolled or will be enrolled in outpatient cardiovascular services at the VA
Tennessee Valley Healthcare System
Exclusion Criteria:
Patients who
1. are transferred to a long-term care facility or skilled nursing facility
2. are assigned to another Veterans Health Administration medical center,
3. have a discharge primary or secondary discharge diagnosis code for dementia,
schizophrenia, or organic brain syndrome,
4. cannot speak or understand English or give written informed consent,
5. are enrolled in hospice or palliative care
6. are participating in another trial that prohibits participation in this trial
7. have a baseline LDL> 200mg/dL in proximity to admission suggestive of familial
hypercholesterolemia (FH) or a known diagnosis of FH
8. require clonidine or minoxidil for blood pressure control prior to the index
admission
9. are enrolled in the Nashville preventative cardiovascular clinic for hypertension
10. have a urinary drug screen positive for cocaine in the last 12 months
11. have plans to move in the next 6 months
We found this trial at
1
site
Click here to add this to my saved trials